InvestorsHub Logo
Followers 21
Posts 2543
Boards Moderated 0
Alias Born 12/07/2013

Re: ziploc_1 post# 115288

Monday, 10/02/2017 3:21:13 PM

Monday, October 02, 2017 3:21:13 PM

Post# of 426859
AS I have posted here numerous times this is a grievous flaw in the study design. Statin intolerant individuals should have been included as a subset . The likelihood of success in this group would be greater and reveal effectiveness if the compound is only marginally beneficial - opening up a huge potential market. With the current study design if the compound is only marginally effective it is possible that no benefit is revealed - shutting down a huge potential market ..... This is an inexcusable flaw in study design
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News